The gold industry standard for risk and cost of drug and vaccine development revisited

E.S. Pronker, T.C. Weenen, H.R. Commandeur, A.D.M.E. Osterhaus, E. Claassen

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Gold dimensions of pharmaceutical drug development indicate that it takes on average 11.9 years, with an investment around US$ 0.8 Billion, to launch one product on the market. Furthermore, approximately 22% of the drug candidates successfully complete clinical testing. These universally acknowledged proportions largely originate from one single, much cited publication; Dimasi et al. [5]. However an additional six articles describing new chemical entities (NCE) development were identified, which contain little, if any, information on vaccines. Published cumulative success rates range from 7% to 78% and investments calculations span US$ 0.8 to 1.7 Billion. Obviously this disserves further clarification? © 2011 Elsevier Ltd.
Original languageEnglish
Pages (from-to)5846-5849
JournalVaccine
DOIs
Publication statusPublished - 2011

Fingerprint

Dive into the research topics of 'The gold industry standard for risk and cost of drug and vaccine development revisited'. Together they form a unique fingerprint.

Cite this